Payment overview · 2025
General Payments
$1,374.75
74 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Ross Horrell, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MT PLEASANT, PA · NPI 1134558885
Verified facts
What the public records show
CMS Open Payments records show Christopher Ross Horrell, PA-C received $1,374.75 in general payments during 2025 across 74 reported records.
ABBVIE INC. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $372.83 | 27.1% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.76 | 16.7% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.44 | 11.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.76 | 11.3% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $113.71 | 8.3% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.05 | 5.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.94 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.28 | 3.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.44 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.45 | 2.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.48 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.53 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.26 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.82 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,374.75 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $203.29 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $198.63 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $164.78 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $161.44 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $119.32 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.18 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.18 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $113.71 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $105.56 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $77.05 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.28 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $50.22 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.44 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 153 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
153 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 606 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 116 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 380 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 91 |
| Omeprazole | Omeprazole | 333 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 243 | 36 |
| Metformin Hcl | Metformin Hcl | 208 | 63 |
| Oxycodone Hcl | Oxycodone Hcl | 199 | 36 |
| Buspirone Hcl | Buspirone Hcl | 185 | 41 |
| Irbesartan | Irbesartan | 183 | 51 |
| Losartan Potassium | Losartan Potassium | 179 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 153 | 31 |
| Potassium Chloride | Potassium Chloride | 150 | 31 |
| Lisinopril | Lisinopril | 147 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 41 |
| Eliquis | Apixaban | 136 | 31 |
| Ibuprofen | Ibuprofen | 135 | 46 |
| Ozempic | Semaglutide | 134 | 27 |
| Furosemide | Furosemide | 132 | 40 |
| Sertraline Hcl | Sertraline Hcl | 116 | 39 |
| Simvastatin | Simvastatin | 103 | 28 |
| Carvedilol | Carvedilol | 95 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 17 |
| Spironolactone | Spironolactone | 87 | 20 |
| Atenolol | Atenolol | 82 | 22 |
| Azithromycin | Azithromycin | 82 | 71 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 23 |
| Prednisone | Prednisone | 79 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 19 |
| Famotidine | Famotidine | 77 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 15 |
| Glipizide | Glipizide | 67 | 21 |
| Meloxicam | Meloxicam | 66 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 13 |
| Trazodone Hcl | Trazodone Hcl | 65 | 16 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 16 |
| Trulicity | Dulaglutide | 61 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Ondansetron Odt | Ondansetron | 53 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 52 | 20 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Baclofen | Baclofen | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 14 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 28 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Metolazone | Metolazone | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 11 |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | 13 |
| Topiramate | Topiramate | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,374.75 · 74 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, FANAPT, Kerendia, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error